# A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

> **NCT00298038** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 299 (actual)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00298038
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-19
- **Primary completion:** 2008-08-15
- **Final completion:** 2008-08-15
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298038, "A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00298038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*